91 related articles for article (PubMed ID: 9617872)
1. Sustained improvement in anemia with low-dose recombinant human erythropoietin therapy in a patient with hypoplastic myelodysplastic syndrome and chromosomal abnormalities.
Tamai Y; Takami H; Nakahata R; Kariya K; Munakata A
Intern Med; 1998 Mar; 37(3):320-3. PubMed ID: 9617872
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.
Stein RS; Abels RI; Krantz SB
Blood; 1991 Oct; 78(7):1658-63. PubMed ID: 1912554
[TBL] [Abstract][Full Text] [Related]
4. Serial changes in endogenous erythropoietin levels in patients with myelodysplastic syndromes and aplastic anemia undergoing erythropoietin treatment.
Yoshida Y; Anzai N; Kawabata H; Kohsaka Y; Okuma M
Ann Hematol; 1993 Apr; 66(4):175-80. PubMed ID: 8485205
[TBL] [Abstract][Full Text] [Related]
5. Sequential observation of clinical and karyotypic evolution in a patient with myelodysplastic syndrome.
Xue YQ; Guo Y; Lin BJ; Zhang GR; Lu DW; Wang MH; Gu YZ; Gong JX; Wang LX
Chin Med J (Engl); 1989 Sep; 102(9):689-94. PubMed ID: 2517082
[TBL] [Abstract][Full Text] [Related]
6. Durable erythroid response after discontinuation of epoetin-alpha: an unexpected outcome in a patient with myelodysplastic syndrome.
Niscola P; Giovannini M; Tendas A; Scaramucci L; Perrotti A; De Fabritiis P
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s160-1. PubMed ID: 23522884
[No Abstract] [Full Text] [Related]
7. Recombinant human erythropoietin in patients with myelodysplastic syndromes.
Schouten HC; Vellenga E; van Rhenen DJ; de Wolf JT; Coppens PJ; Blijham GH
Leukemia; 1991 May; 5(5):432-6. PubMed ID: 2033964
[TBL] [Abstract][Full Text] [Related]
8. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome.
Goy A; Belanger C; Casadevall N; Picard F; Guesnu M; Jaulmes D; Poisson D; Varet B
Br J Haematol; 1993 Jun; 84(2):232-7. PubMed ID: 8398823
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
11. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Stone RM; Bernstein SH; Demetri G; Facklam DP; Arthur K; Andersen J; Aster JC; Kufe D
Leuk Res; 1994 Oct; 18(10):769-76. PubMed ID: 7934135
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis.
Mohr B; Herrmann R; Huhn D
Acta Haematol; 1993; 90(2):65-70. PubMed ID: 8285020
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
Stenke L; Wallvik J; Celsing F; Hast R
Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
[TBL] [Abstract][Full Text] [Related]
16. [Rapid aggravation of splenomegaly by administration of erythropoietin in a case of myelodysplastic syndrome].
Sato T; Wakabayashi Y; Sato T; Nishikawa T; Tashiro Y; Chiba S
Rinsho Ketsueki; 1992 Dec; 33(12):1857-62. PubMed ID: 1479699
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].
Zhang H; Qin T; Xu Z; Fang L; Pan L; Hu N; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):18-23. PubMed ID: 24602726
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia.
Takahashi M; Aoki A; Mito M; Nikkuni K; Ohtsuka T; Saitoh H; Moriyama Y; Shibata A
Hematol Pathol; 1993; 7(3):153-8. PubMed ID: 8244908
[TBL] [Abstract][Full Text] [Related]
19. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with cyclosporin A of myelodysplastic syndrome with erythroid hypoplasia associated with t(6;8)(q15;q22).
Takata S; Kojima K; Fujii N; Kaneda K; Yoshida C; Hashimoto D; Asakura S; Shinagawa K; Tanimoto M
Cancer Genet Cytogenet; 2003 Jan; 140(2):167-9. PubMed ID: 12645657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
